Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. reduced its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 7.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 37,306 shares of the biotechnology company’s stock after selling 2,815 shares during the quarter. Corebridge Financial Inc.’s holdings in Anavex Life Sciences were worth $401,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Essential Planning LLC. purchased a new position in shares of Anavex Life Sciences in the fourth quarter valued at approximately $4,437,000. Virtu Financial LLC purchased a new position in Anavex Life Sciences in the 4th quarter valued at approximately $967,000. Barclays PLC grew its stake in shares of Anavex Life Sciences by 70.4% in the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock worth $882,000 after acquiring an additional 64,101 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Anavex Life Sciences by 2.8% during the third quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after acquiring an additional 51,946 shares during the period. Finally, Atria Wealth Solutions Inc. purchased a new position in Anavex Life Sciences in the fourth quarter valued at $291,000. 31.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. D. Boral Capital restated a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a report on Monday. HC Wainwright restated a “buy” rating and set a $42.00 target price on shares of Anavex Life Sciences in a research note on Monday.

Anavex Life Sciences Trading Up 14.7 %

AVXL stock opened at $8.72 on Thursday. The company has a market capitalization of $741.76 million, a P/E ratio of -15.85 and a beta of 0.80. The business has a 50 day simple moving average of $8.70 and a 200-day simple moving average of $8.48. Anavex Life Sciences Corp. has a twelve month low of $3.25 and a twelve month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. Research analysts predict that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.